IMATINIB HAS LIMITED THERAPEUTIC ACTIVITY FOR HYPEREOSINOPHILIC SYNDROME PATIENTS WITH UNKNOWN OR NEGATIVE PDGFRα MUTATION STATUS

Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res
Hlavní autoři: Jain, Nitin, Cortes, Jorge, Quintás-Cardama, Alfonso, Manshouri, Taghi, Luthra, Raja, Garcia-Manero, Guillermo, Kantarjian, Hagop, Verstovsek, Srdan
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4422052/
https://ncbi.nlm.nih.gov/pubmed/19013640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.10.004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky